ReviewExpert opinion on biological therapy2008
Oncolytic measles virus strains in the treatment of gliomas.
Review in Expert opinion on biological therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 73 citations in OpenAlex.
- Measles virus for cancer therapy.Current topics in microbiology and immunology · 2009Trial
- Heat up and Destroy: Immunotherapy of "Cold" Tumors Using the Example of Glioblastoma.International journal of molecular sciences · 2026Review
- Review
- Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma.International journal of molecular sciences · 2024Review
- Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial.Nature communications · 2024Article
- Anticancer Activity of Measles-Mumps-Rubella MMR Vaccine Viruses against Glioblastoma.Cancers · 2023Article
- Self-replicating vehicles based on negative strand RNA viruses.Cancer gene therapy · 2023Review
- Positioning SUMO as an immunological facilitator of oncolytic viruses for high-grade glioma.Frontiers in cell and developmental biology · 2023Review
- Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with anMolecular therapy. Methods & clinical development · 2022Article
- Oncolytic Viruses in the Therapy of Lymphoproliferative Diseases.Molecular biology · 2022Article
- Synthetic and systems biology principles in the design of programmable oncolytic virus immunotherapies for glioblastoma.Neurosurgical focus · 2021Review
- Introduction to immunotherapy for brain tumor patients: challenges and future perspectives.Neuro-oncology practice · 2020Review
- Viral vector: potential therapeutic for glioblastoma multiforme.Cancer gene therapy · 2020Review
- Virotheranostics, a double-barreled viral gun pointed toward cancer; ready to shoot?Cancer cell international · 2020Review
- Syncytia Formation in Oncolytic Virotherapy.Molecular therapy oncolytics · 2019Review
- Biological intratumoral therapy for the high-grade glioma part II: vector- and cell-based therapies and radioimmunotherapy.CNS oncology · 2019Review
- Receptor-Targeted Glial Brain Tumor Therapies.International journal of molecular sciences · 2018Review
- Article
- Integrating oncolytic viruses in combination cancer immunotherapy.Nature reviews. Immunology · 2018Review
- Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.Current cancer drug targets · 2018Review
Corrections and comments
- Erratum issuedMyers, Rae [added]; Peng, Kah Whye [added]; Russell, Stephen J [added]
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundRecurrent gliomas have a dismal outcome despite use of multimodality treatment including surgery, radiation therapy and chemotherapy.
objectiveIn this article the authors discuss potential applications of oncolytic measles virus strains as novel antitumor agents in the treatment of gliomas.
methodsImportant aspects of measles virus development as an anticancer therapeutic agent including engineering, retargeting and combination studies with other therapeutic modalities are discussed. The translational process that led to the first clinical trial of an engineered measles virus derivative in patients with recurrent glioblastoma multiforme is also described. RESULTS/
conclusionsOncolytic measles virus strains hold promise as novel antitumor agents in the treatment of gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.